0001564590-21-017177.txt : 20210401 0001564590-21-017177.hdr.sgml : 20210401 20210401065321 ACCESSION NUMBER: 0001564590-21-017177 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20210401 FILED AS OF DATE: 20210401 DATE AS OF CHANGE: 20210401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 21795986 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190847081 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 bntx-6k_20210401.htm 6-K bntx-6k_20210401.DOCX.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF APRIL 2021

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐


DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

 

On April 1, 2021, BioNTech SE (the “Company”) and Pfizer Inc. announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study through March 13, 2021, showing that the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3% effective against COVID-19, measured seven days through up to six months after the second dose. The press release is attached hereto as Exhibit 99.1.

 


SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BioNTech SE

 

 

 

 

 

 

 

By:

/s/ Dr. Sierk Poetting

 

 

Name: Dr. Sierk Poetting

 

 

Title:   Chief Financial Officer

Date: April 1, 2021


EXHIBIT INDEX

 

 

 

 EX-99.1 2 bntx-ex991_6.htm EX-99.1 bntx-ex991_6.htm

Exhibit 99.1

 

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

 

 

•

Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose

 

•

Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the U.S. Food and Drug Administration

 

•

Vaccine was 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent

 

•

Vaccine safety now evaluated in more than 44,000 participants 16 years of age and older, with more than 12,000 vaccinated participants having at least six months follow-up after their second dose

 

•

The companies plan to share these results with worldwide regulatory agencies soon

 

New York and Mainz, Germany, April 1, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study through March 13, 2021, showing that the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3% effective against COVID-19, measured seven days through up to six months after the second dose. The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA). Safety data from the Phase 3 study has also been collected from more than 12,000 vaccinated participants who had a follow-up time of at least six months after the second dose, demonstrating a favorable safety and tolerability profile.

 

“These data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine’s overall effectiveness.”  

 

“It is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a longer-term follow-up,” said Ugur Sahin, CEO and Co-founder of BioNTech. “These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population.”  

 

About the Analysis

 

The updated analysis of the Phase 3 clinical trial was conducted in accordance with guidance from the FDA for all companies investigating COVID-19 vaccines to review safety and efficacy at key milestones.

 

Results from this analysis of 46,307 trial participants build upon and confirm previously released data and demonstrate strong protection against COVID-19 through six months post-second dose. From the 927 confirmed symptomatic cases of COVID-19 in the trial, 850 cases of COVID-19 were in the placebo group and 77 cases were in the BNT162b2 group, corresponding to vaccine efficacy of 91.3% (95% confidence interval [CI, 89.0, 93.2]).

 

32 cases of severe disease, as defined by the CDC, were observed in the placebo group versus none in the BNT162b2 vaccinated group, indicating that the vaccine was 100% efficacious in this analysis against severe disease by the CDC definition (95% CI, [88.0,100.0]). 21 severe cases, as defined by

1

 

the FDA, were observed in the placebo group versus one case in the BNT162b2 vaccinated group, indicating 95.3% efficacy by the FDA definition (95% CI, [71.0, 99.9]).

  

Efficacy was generally consistent across age, gender, race and ethnicity demographics, and across participants with a variety of underlying conditions.

 

A total of 697 cases of COVID-19 were observed in the United States; 647 cases of COVID-19 were observed in the placebo group versus 50 in the vaccine group, indicating vaccine efficacy of 92.6% (95% CI, [90.1, 94.5]).

 

In South Africa, where the B.1.351 lineage is prevalent and 800 participants were enrolled, nine cases of COVID-19 were observed, all in the placebo group, indicating vaccine efficacy of 100% (95% CI, [53.5, 100.0]). In an exploratory analysis, the nine strains were sequenced and six of the nine were confirmed to be of the B.1.351 lineage. These data support previous results from immunogenicity studies demonstrating that BNT162b2 induced a robust neutralizing antibody response to the B1.351 variant, and although lower than to the wild-type strain, it does not appear to affect the high observed efficacy against this variant.1

No serious safety concerns were observed in trial participants up to six months after the second dose. Side effects were generally consistent with previously reported results. Vaccine safety has now been evaluated in more than 44,000 participants aged 16 years and older with more than 12,000 vaccinated participants having at least six months of follow-up after their second dose.

 

Pfizer and BioNTech plan to submit detailed data for scientific peer review and potential publication in the near future.

 

The Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine.com.

 

The vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorizations Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

 

AUTHORIZED USE IN THE U.S.:

The Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.

 

IMPORTANT SAFETY INFORMATION FROM U.S. FDA EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION:

 

•

Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine

•

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine

•

Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/)

•

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine

•

The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients

2

 

•

In clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%)

•

Severe allergic reactions, including anaphylaxis, have been reported following the Pfizer-BioNTech COVID-19 Vaccine during mass vaccination outside of clinical trials. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 Vaccine

•

Available data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy

•

Data are not available to assess the effects of Pfizer-BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretion

•

There are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series

•

Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967. The reports should include the words “Pfizer-BioNTech COVID-19 Vaccine EUA” in the description section of the report

•

Vaccination providers should review the Fact Sheet for Information to Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use Authorization

•

Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine-us.com

 

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

 

Pfizer Disclosure Notice

The information contained in this release is as of April 1, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

 

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) (including qualitative assessments of available data, potential benefits, expectations for clinical trials, anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the topline data outlined in this release), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data (including the topline data outlined in this release); the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus

3

 

variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data (including the topline data outlined in this release) are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program (including the topline data outlined in this release) will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when a Biologics License Application for BNT162b2 may be filed in the U.S. and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including a potential Biologics License Application in the U.S. or any requested amendments to the emergency use authorization) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

 

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

 

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

 

BioNTech Forward-looking Statements

This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including a potential second booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA

4

 

sequence); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.

 

For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

 

Pfizer Contacts:

 

Media Relations

Jerica Pitts

+1 (347) 224-9084

Jerica.Pitts@pfizer.com

 

Investor Relations

Chuck Triano

+1 (212) 733-3901

Charles.E.Triano@Pfizer.com  

 

BioNTech Contacts:

 

Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513

Media@biontech.de  

 

Investor Relations

Sylke Maas, Ph.D.

+49 (0)6131 9084 1074

Investors@biontech.de

 

 

 

 

1 

New England Journal of Medicine. Neutralizing Activity of BNT162b2-Elicited Serum; March 8, 2021. Available at https://www.nejm.org/doi/full/10.1056/NEJMc2102017

 

5

 

 GRAPHIC 3 guzjsxkjfy3c000001.jpg GRAPHIC begin 644 guzjsxkjfy3c000001.jpg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end GRAPHIC 4 guzjsxkjfy3c000004.jpg GRAPHIC begin 644 guzjsxkjfy3c000004.jpg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end GRAPHIC 5 guzjsxkjfy3c000003.jpg GRAPHIC begin 644 guzjsxkjfy3c000003.jpg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end GRAPHIC 6 g5u1syxl3vxw000001.jpg GRAPHIC begin 644 g5u1syxl3vxw000001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P!)YYOM$O[V M3[Y_B/K4?VB;_GM)_P!]&BX_X^9?]\_SJ.I/FVW MTG_?1J.B@5V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[2?\ ?1H^T3?\ M]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DGVB;_GM)_WT:/M M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[2?\ ?1H^ MT3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DGVB;_GM)_W MT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[2?\ M?1H^T3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DGVB;_G MM)_WT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[ M2?\ ?1H^T3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DRW M=RAREQ*I]G(JS%K>K0?ZK4[Q,=A.V/YU0HH&I-;,Z"W\;>(+8\:@TB^DJ*WZ MXS6Y9?$Z[0@7MA#*O]Z%BA_(YK@Z*9K'$58[2/9=-\<:'J)"&X-M(?X+@;?U MZ?K71 AE#*001D$=Z^>*U=)\1ZIHKC[)87^9#^';\,47.NGCWM-'N=% MM_#YF?PJA9BQ\Y^2<]Z\@KUWX>?\BI'_ -=G_G31VX!_O?D=7111 M3/8"BBB@ HHHH **** "BBB@ HHHH **** "BBD9E12S$*H&22>!0 M%IBJ4-V>J$ M@#). *RKOQ)HMCD7&I6X8=55M[?DN37C-[J^HZB3]LO9Y@?X6<[?RZ52I7.2 M>8/[,3U>Z^)&C0\01W-P?54"C]3G]*R+CXH3'(MM,1?0R2EOT %>?T47.>6- MK/K8ZV;XC:[+G9]EA_W(L_S)JC+XT\0S?>U)Q_N(J_R%8%%(R=>J]Y,TW\1Z MW(9C_6JE%!#G)[LG>\NI,;[F9L=,N33/M$ MW_/:3_OHU'103=DGVB;_ )[2?]]&C[1-_P ]I/\ OHU'10%V2?:)O^>TG_?1 MJ07]X.EW.,?]-#5>B@=V7UUO5D.4U.]4^UPX_K5B/Q3KL7W=5N3_ +S[OYUD M44#52:V9TD7CSQ%%UO5D'H\*?T%:,'Q,U9.)K6TD'LK*?Y_TKBJ*9HL156TF M>E6WQ0MVP+K394]3%(&_0@5LVOCS0+K :Z>!CVFC(_49'ZUXY110$OGE0?P3_.# M^)Y_(T7.B&8+[2/:Z*\_TWXFQ,534K(H>\D!R/\ OD_XFNQTW6]-U9-UC>1R MG&2@.&'U4\TSLIUZ=3X67Z***#4**** "BBB@ HHHH **** "BBB@ HHHH * M*** .3\3LRZE& Q'[D=#[M6+YC_WV_.MGQ1_R$X_^N(_FU8E?%9@W]:GZFBV M'>8_]]OSH\Q_[[?G3:*XKL!WF/\ WV_.CS'_ +[?G3:*+L"_INK3Z?-G)>)O MO(3U]Q[UV=K=0WD"S0MN4_F#Z&O/:M6%_-I\_F1'@_>4]&%>KE^92P[Y)ZQ_ M(35SOJ*JV-_#J$'F1-R/O*>JFK5?5PG&<5*+NF0%%%%4 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=R2/ MYC?.W4]Z]$KSF3_6-]37S^>MI4_G^A40\Q_[[?G1YC_WV_.FT5\[=E#O,?\ MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_ M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_ M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_ M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_ M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ MOM^==9X8);39"23^^/7Z+7(UUOA?_D&2?]=C_):]7)V_K2]&*6QMT445]:0% M%%% !1110!P/Q.D=+?3=CLN7DS@X[+7G/VB;_GM)_P!]&O1/BC_Q[:;_ +\G M\EKS>DSQ,8_WS)/M$W_/:3_OHT?:)O\ GM)_WT:CHI'+=DGVB;_GM)_WT:/M M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[2?\ ?1H^ MT3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DGVB;_GM)_W MT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[2?\ M?1H^T3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DGVB;_G MM)_WT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[ M2?\ ?1H^T3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DGV MB;_GM)_WT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79] 6 M'.G6I/\ SQ3^0JQ5;3_^0;:_]<4_D*LU1])'9!1110,**** "BBB@ HHHH * M*** "BBB@ HHHH **CFGAMHFEGE2*->KNP 'XFN5U/XAZ19;DM1)>R#^Y\J? M]]'^@-!$ZL(+WG8ZZFNZQH7=@JCJ6. *\FU#XAZU=Y6W,5HA_P">:Y;\S_0" MN:NK^\OGWW=U-.WK(Y;'YTKG'/'P7PJY[-=^+=!LB1+J4+,.T69/_0 MORYV200_[D0/_H6:Y6B@Q>)K/>1N2^,?$$WWM3E'^XJK_(54?Q!K,F=^JWI! MZCSV _G6=12,W4F]VRTVIW[G+WURV/65C_6HVNKASE[B5CZER:AHH)YF2?:) MO^>TG_?1H^T3?\]I/^^C4=% KLD^T3?\]I/^^C1]HF_Y[2?]]&HZ* NR3[1- M_P ]I/\ OHT?:)O^>TG_ 'T:CHH"[)/M$W_/:3_OHT?:)O\ GM)_WT:CHH"[ M)/M$W_/:3_OHT?:)O^>TG_?1J.B@+LD^T3?\]I/^^C1]HF_Y[2?]]&HZ* NR M3[1-_P ]I/\ OHT?:)O^>TG_ 'T:CHH"[)/M$W_/:3_OHT?:)O\ GM)_WT:C MHH"[)/M$W_/:3_OHT?:)O^>TG_?1J.B@+LD^T3?\]I/^^C1]HF_Y[2?]]&HZ M* NR3[1-_P ]I/\ OHT?:)O^>TG_ 'T:CHH"[)/M$W_/:3_OHUWWPQD=[G4M M[LV$CQDY[M7GM>@?"[_CYU+_ '(_YM3.G"/]]$](HHHIGN!1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !7CGCB:5?&-^JR. /+X#'_ M )YK7L=>,^.O^1RO_P#MG_Z+6DSAQ_\ "7K_ )F#]HF_Y[2?]]&C[1-_SVD_ M[Z-1T4CR+LD^T3?\]I/^^C1]HF_Y[2?]]&HZ* NR3[1-_P ]I/\ OHU['N;U M/YUXQ7LU,[L&_B^1X[15Z[\//^14C_Z[ M/_.FCMP'\7Y'5T444SV HHHH **** "BBB@ HHHH **** "FNZ11M)(RHBC+ M,QP />L?7_$UAX?A_?MYEPPRD"'YC[GT'O7E6N>)M1UZ4_:)=EN#\L"'"CZ^ MI]S0:S**1Y57$5*F[T"BBBD8!1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %.1WC=71F5E.0RG!%-HH ZW1_B!JFGE8 M[P_;8!Q\YPX^C=_QS7HFC>)=,UQ/]$GQ-C)@D^5Q^'?ZC->'4Y'>*19(V9'4 MY5E."#3N==+&5(:/5'T-17FGAWXA2P;+;6'?Z]?K7H\$\5S MD\$BR1.,JZG((IGJTJT*JO$DHHHH-0HHHH **** "BBB@ HHHH **** .2\4 M?\A./_KB/YM6)6WXH_Y"W^0FKGHE%9FDZQ'J";'PEP!RO][W%:=?7T:T*T%.#NB HHHK0 MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ KSF3_6-]37HU>VF_P"_)_):\WKT MCXH_\>VF_P"_)_):\WI,\3&?QG_70****1RA1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >_Z?\ \@VU M_P"N*?R%6:K:?_R#;7_KBG\A5FJ/I([(****!A1110 4444 %%%% !1110 4 M45R_B3QK9Z)NMX-MS?#CRP?E3_>/].OTH(G4C!S4SMP?VOD>.W'_ !\R_P"^?YU'76R_#[7GF=A'!@L2/WHIO_"O-?\ M^>=O_P!_108/#U;_ LY2BNK_P"%>:__ ,\[?_OZ*/\ A7FO_P#/.W_[^B@/ MJ]7^5G*45U?_ KS7_\ GG;_ /?T4?\ "O-?_P">=O\ ]_10'U>K_*SE**ZO M_A7FO_\ /.W_ ._HH_X5YK__ #SM_P#OZ* ^KU?Y6:_P#\\[?_ M +^B@/J]7^5G*45U?_"O-?\ ^>=O_P!_11_PKS7_ /GG;_\ ?T4!]7J_RLY2 MBNK_ .%>:_\ \\[?_OZ*/^%>:_\ \\[?_OZ* ^KU?Y6= MO_W]%'_"O-?_ .>=O_W]% ?5ZO\ *SE**ZO_ (5YK_\ SSM_^_HH_P"%>:__ M ,\[?_OZ* ^KU?Y6=O\ ]_11_P *\U__ )YV_P#W]% ? M5ZO\K.4HKJ_^%>:__P \[?\ [^BC_A7FO_\ /.W_ ._HH#ZO5_E9RE%=7_PK MS7_^>=O_ -_11_PKS7_^>=O_ -_10'U>K_*SE**ZO_A7FO\ _/.W_P"_HH_X M5YK_ /SSM_\ OZ* ^KU?Y6=O_P!_ M10'U>K_*SE**ZO\ X5YK_P#SSM_^_HH_X5YK_P#SSM_^_HH#ZO5_E9RE%=7_ M ,*\U_\ YYV__?T4A^'NOX_U4!]O-%(7U>K_ "LY6BNCD\"^(HUW?8 X[[94 M/]:Q[S2[_3S_ *99SP$%%%% !7KOP\_Y%2/_KL_\Z\BKUWX>?\ M(J1_]=G_ )TT=N _B_(ZNBBBF>P%%%% !1110 4444 %%%% !7'^+?&D>D!K M*P*2WQ&&;JL/U]6]OS]*;XT\7#2HFTZQ?_3G7YW4_P"I!_\ 9C^G6O*B2S%F M)))R2>])L\_%8OE]R&X^>>6ZG>>>1I)7.6=CDDU'112/*"BBB@ HHHH **** M "BBB@ HHIR1O*VV-&=O11DT -HK0BT+5YQF+2[Q@>X@;'YXJY'X.\02?=TR M4<'_?T4'X>Z^ 2(H#["44P^KU?Y6]\/W'[LF6U8YD@8\'W'H:PZ*"HSE!\T3WO2]5M-8LEN[.3>AX M([H?0CL:NUX7H6NW>@7XN+<[D;B6(GY9!_CZ&O:=,U*VU>PCO+1]T3COU4]P M?>J/9PV)556>Y;HHHH.H**** "BBB@ HHHH **** .2\4?\ (3C_ .N(_FU8 ME;?BC_D)Q_\ 7$?S:L2OB@?\ ^O7(4 D'(."*[,'C*F%GS1VZH&KGI%%< M_HVN^9MMKQL/T20_Q>Q]ZZ"OL,-B:>(ASP?_ "&K!1116X@HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O.9/]8WU->C5Q M[^'=0+L0L?)_OUXF6 M:_P#\\[?_ +^B@Y_J]7^5G*45U?\ PKS7_P#GG;_]_11_ MPKS7_P#GG;_]_10'U>K_ "LY2BNK_P"%>:__ ,\[?_OZ*/\ A7FO_P#/.W_[ M^B@/J]7^5G*45U?_ KS7_\ GG;_ /?T4?\ "O-?_P">=O\ ]_10'U>K_*SE M**ZO_A7FO_\ /.W_ ._HH_X5YK__ #SM_P#OZ* ^KU?Y6:_P#\ M\[?_ +^B@/J]7^5G*45U?_"O-?\ ^>=O_P!_11_PKS7_ /GG;_\ ?T4!]7J_ MRLY2BNK_ .%>:_\ \\[?_OZ*/^%>:_\ \\[?_OZ* ^KU?Y6=O_W]%'_"O-?_ .>=O_W]% ?5ZO\ *SE**ZO_ (5YK_\ SSM_^_HH_P"% M>:__ ,\[?_OZ* ^KU?Y6=O\ ]_11_P *\U__ )YV_P#W M]% ?5ZO\K.4HKJ_^%>:__P \[?\ [^BC_A7FO_\ /.W_ ._HH#ZO5_E9RE%= M7_PKS7_^>=O_ -_11_PKS7_^>=O_ -_10'U>K_*SE**ZO_A7FO\ _/.W_P"_ MHH_X5YK_ /SSM_\ OZ* ^KU?Y6>J:?\ \@VU_P"N*?R%6:AM(VALX(G^\D:J M<>H%34SWEL%%%% PHHHH **** "BBB@ HHKS;QOXP,S2:3ITF(@=L\RG[Q_N MCV]3W^G4,JU:-*/,R3Q;XZ;=)I^CR8QE9+E3^B?X_EZUYZ2222 /$)(!M8Q[F9?\:D_P"%>:__ ,\[?_OZ*!_5ZO\ *SE* M*ZO_ (5YK_\ SSM_^_HH_P"%>:__ ,\[?_OZ*8_J]7^5G*45U?\ PKS7_P#G MG;_]_11_PKS7_P#GG;_]_10'U>K_ "LY2BNK_P"%>:__ ,\[?_OZ*/\ A7FO M_P#/.W_[^B@/J]7^5G*45U?_ KS7_\ GG;_ /?T4?\ "O-?_P">=O\ ]_10 M'U>K_*SE**ZO_A7FO_\ /.W_ ._HH_X5YK__ #SM_P#OZ* ^KU?Y6:_P#\\[?_ +^B@/J]7^5G*45U?_"O-?\ ^>=O_P!_11_PKS7_ /GG;_\ M?T4!]7J_RLY2BNK_ .%>:_\ \\[?_OZ*/^%>:_\ \\[?_OZ* ^KU?Y6=O_W]%'_"O-?_ .>=O_W]% ?5ZO\ *SE*] ^%W_'SJ7^Y'_-J MRO\ A7FO_P#/.W_[^BNK\$>'-0T&:]:^6,"54"['W=,Y_G0;X:C4C53:.RHH MHIGL!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C/ MCK_DO^9SM%%%(\@** M** "O9J\9KV:F=N#^U\CHJ***9[ 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(RJZE7 M4,I&"",@TM% '(:[X!T_45>6P"V=T>0%'[MOJ.WX?D:\PU#3[K2[Q[2\B,A'J#W%>_5A>*/#L.OZ:R!56[C!,$GH?[I]C_]>E8X<1A(S7-#1GBE%.DC M>*1HY%*NA*LIZ@CJ*;2/("BBB@ IT;M%(LB,5="&4CL13:* /?\ 3KM;_3;: M[7I-$KX],CI5FN9\!7)N/"5LI.3"SQG\\C]"*Z:J/HJ?\ (J1_]=G_ )UY%7KOP\_Y%2/_ *[/_.FCMP'\7Y'5T444SV HHHH M**** "BBB@ K!\5^(D\/Z877:UW+E8$/KW8^P_PK:GGBM;>2>9PD4:EG8]@* M\/\ $&LRZ[J\MY)D)]V)#_ @Z#^OU-#.7%U_90LMV9TTTEQ,\TKEY'8LS,>2 M33***D\0**** "BBB@ HHJ[IND7VKW'DV-N\K?Q$<*OU/04#2;=D4JFM;2YO M9A%:P232'^&-2Q_2O2-&^&]K %EU68W$G_/*,E4'U/4_I7:6MG;64(AM8(X8 MQ_#&H44[';2P$Y:S=CRNP^'>LW6&N3#:(?[[;F_(?XUTMG\-=+AP;NYN+EAU M PBG\.3^M=K13L=L,'2CTN8]KX5T*S_U6EVY([R+YA_\>S6K'%'"FR*-47T5 M<"GT4'1&$8[*P4444%!1110 4444 %%%% !1110!4N=+T^\S]IL;:;/=X@36 M+=^ ] NLE;5X&/\ %#(1^AR/TKI:*")4X2^)'G-]\,7 +:?J ;T2=!I2VT/G>BO;=6\)Z/K 9I M[58YF_Y;0_*V?4]C^.:\_P!;\ ZEI@::T_TVW')V+AU^J]_PHL<%7!U*>JU1 MR5%!!!P1@BBDHH*A- MPDI1/H:.1)8UDC8,C@,K Y!!Z&G5P'P[\0&6-M&N7RR O;DGJ.Z_AU'X^E=_ M5'OT:JJP4D%%%%!H%%%% !1110 4444 ?/!_P#!!JYZ0"",@Y!HKD-' MUQK,B"X):W['J4_^M76HZR('1@RL,@@\&OL,)C*>*AS1WZHAJPZBBBNL0444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '(>)O^0J/^N0_F:QJ MV?$W_(5'_7(?S-8U?$8__>I^IHM@HHHKC **** /0[?_ (]HO]P?RJ6HK?\ MX]HO]P?RJ6OT&'PHS"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBJ&M:K#HNE37TW.P81?[S'H*!-J*NSF_'?BU04CP:]9U9WZ!1112,0HHHH M**** "BM?1O#>IZZ_P#HD&(-^G M'ZUZA%%'#&L<4:QHHP%08 _"GT6/0A@(+XG'=&L\>1IEJI'1C&&/YGFM.BF=,:-..R$5510JJ%4= !BEHHH-0HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "O&?'7_ ".5_P#]L_\ T6M>S5XSXZ_Y'*__ .V?_HM:3.',/X2]?\SG:*** M1Y 4444 %>S5XS7LU,[<']KY'14444SV HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@#R3XA:8++Q#]IC7$=VGF'_?'#?T/XUR5>H_$VV#Z-:7./FBGV?@R MG/\ Z"*\NI'A8N'+5=@HHHI'.%%%% 'J7PRD)T*ZCR/EN2?S5?\ "NVKA/AA M_P @V_\ ^NR_RKNZH]W"_P &(4444'0%%%% !7"?$_\ Y!MA_P!=F_E7=UPG MQ/\ ^0;8?]=F_E0SGQ?\&1YE1114GA!1110 5Z[\//\ D5(_^NS_ ,Z\BKUW MX>?\BI'_ -=G_G31VX#^+\CJZ***9[ 4444 %%%% !113)I4@@DFE;;'&I9B M>P R: .%^)&M>3;1:1"^&E_>38_NCH/Q//X#UKS2KNKZC)JVJW-])G,KD@'L MO0#\!BJ5(\"O5]I4<@HHHI&(4444 %%%>A>"_!F\1ZKJD7R\-! PZ^C,/3T% M!I2I2JRY8F?X8\"SZHJ7FH[H+,\J@X>0?T'O_P#KKTZSLK;3[9;>T@2&%>BJ M/\Y/O5BBJ/;HT(4EIN%%%%!L%%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% '-^(O!MAK@:9 +:]QQ*HX8_[0[_ %ZUY1JFDWFC7C6M M[$4<=".58>H/<5[W6?K.C6FN6#6MVF1U1Q]Y#ZBE8X\1A(U/>CHSP>BM+6]$ MN]"OVM;E<@\QR ?+(OJ/\*S:1X\HN+LPHHHH$%%%% $UI=36-Y#=0-MEB<.I M]Q7NVE:C%JNEV]]#]V9,X_NGN/P.17@=>@_#35MLEQI,C<-^^BSZ]&'\C^!I MH[<#5Y9\CV9Z/1113/8"BBB@ HHHH **** .2\4?\A./_KB/YM6)6WXH_P"0 MG'_UQ'\VK$KXG,?]ZGZFBV"BBBN( HHHH [*;2X=1TNW#?+*L2[9 .G'0^U< MG=6LUG.T,R[6'Y$>HKN[+_CQM_\ KDO\J9?V$.H0>7*.1]UQU4U]7C,MCB*: MG#25OO)3L<#15J^L)M/G\N4<'[K#HPJK7R\X2A)QDK-%!1114 %%%% !6GI6 ML2:>^Q\O;D\K_=]Q6916M&M.C-3@[,#T2&:.XB66)PZ,."*DKA=-U2;3ILK\ MT3'YT/?Z>]=G:7<-[ LT+;E/4=P?0U]=@C:[J:Z/HMU?'&Z-/D![L> /SKP MIW:21I'8L[$LQ/_Y>_7T['J8;!I+FJ?<-CC2&-8XD5$4855& !["G444ST0HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "O&?'7_(Y7__ &S_ /1:U[-7C/CK_DS5XS7LU,[<']KY'14444SV HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@#E/B& ?"C\=)DQ7D5>M?$:0)X7"G_ ):7 M"*/R)_I7DM)GC8[^+\@HHHI'&%%%% 'IOPP_Y!M__P!=E_E7=UPGPP_Y!M__ M -=E_E7=U1[N$_@Q"BBB@Z HHHH *X3XG_\ (-L/^NS?RKNZX3XG_P#(-L/^ MNS?RH9SXO^#(\RHHHJ3P@HHHH *]=^'G_(J1_P#79_YUY%7KOP\_Y%2/_KL_ M\Z:.W ?Q?D=71113/8"BBB@ HHHH *Y/X@ZE]B\.FW1L27;^7[[1RW]!^-=9 M7DWQ%O\ [5XB6U5LI:QA]0HJE"W4****#8**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R]>T.WU[37M9 M@%<HKQ.]LI]/O9K2Y39-$VUA_7Z5] 5Q'Q"T 7=C_:UNG[^W&) M0!]Z/U_#^6?2DSAQE#GCSK='EU%%%(\@**** "KND7[Z7JUK>IG]S(&('=>A M'XC(JE10--IW1]#(ZR(KH0RL,@CN*=7/>"+\W_A:U+-F2#,#?\!Z?^.E:Z&J M/HH24XJ2ZA11104%%%% !1110!R7BC_D)Q_]<1_-JQ*V_%'_ "$X_P#KB/YM M6)7Q.8_[U/U-%L%%%%<0!1110!Z#9?\ 'C;_ /7)?Y5/4%E_QXV__7)?Y5/7 MZ!3^!>AF0W5K#>0-#,NY3^8/J*XO4M+FTZ7#?-$Q^1P.OL?>NZIDT,=Q$T4J M!T8<@UQ8[ 0Q4;[26S_S&G8\ZHK4U;1Y-/?S$R]N3PW=?8UEU\C6HSHS<)JS M+"BBBL@"BBB@ JU8W\VGS^9$>#]Y3T855HJX3E"2E%V: [ZPOX=0@\R(\C[R M'JIJU7GMK=36U?5Y?F4<0N2>DO MS(:L7Z***]404444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R'B;_D*C_KD/ MYFL:MGQ-_P A4?\ 7(?S-8U?$8__ 'J?J:+8****XP"BBB@#T.W_ ./:+_<' M\JEJ*W_X]HO]P?RJ6OT&'PHS"BBBJ **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** /.OB;J?-II:-T_?R#]%_]F_2O/*U_$]__ &EXDOK@'*>8 M43_=7Y1_+/XUD4CP,1/GJ-A1112,0HHHH *]*\ ^&!#$FLWD?[UQ_HZ,/NK_ M 'OJ>WM]:Y3PAH7]NZTJ2*3:P?O)CZCLOXG],U[0 % ' IH]#!4.9^TE M\A:***9ZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 5XSXZ_Y'*__ .V?_HM:]FKQ MGQU_R.5__P!L_P#T6M)G#F'\)>O^9SM%%%(\@**** "O9J\9KV:F=N#^U\CH MJ***9[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !112,RHA9B JC))Z 4 >>_$ M^\&+"Q!Y^:9A^@_]FKSJM?Q-JW]M:]<7:D^5G9%G^X.GY]?QK(I'@8BI[2HY M(****1B%%%% 'IWPP4_V7?-V,X _[Y_^O7=5RGP]M#;>%DD88-Q*TH^G"C_T M&NKJCWL,K4HH****#<**** "N$^)_P#R#;#_ *[-_*N[KA/B?_R#;#_KLW\J M&<^+_@R/,J***D\(**** "O7?AY_R*D?_79_YUY%7KOP\_Y%2/\ Z[/_ #IH M[G?#?1Q!8RZK* MO[R3^)'Z5YM;P275S%;Q#,DKA%'J2<"O?+*TCL+&"TB&(X4"+^ I MH[L!3YIN;Z$]%%%,]<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "FNBR(R.H96&&!'!%.HH \+\0Z2VBZW<6 M7/EJVZ(GNAY'^'X5EUZ7\3--$EG:ZDB_-$WE2'_9/(_(Y_.O-*1X&(I^SJ.( M4444C$**** /0?AA>8EO[$MU59E'TX/\UKT>O&_ EU]F\6VHSA9@T;?B"1^H M%>R4T>S@97I6[!1113.P**** "BBB@#DO%'_ "$X_P#KB/YM6)6WXH_Y"H++_CQM_P#K MDO\ *IZ_0*?P+T,PHHHJP$=%D0HZAE88((X-*ARRWZ,:=CS>BNAUC03'NN;-,=O<>WM7/5\?B<-4P\^ M2:_X):=PHHHKG **** "GPS202K+$Y1U.013**:;3N@.TTG6(]03RWPEP!RO M9O<5J5YPCLCAT8JRG((/(KK='UQ;L+;W)"S] W9__KU]/EV:*K:E6^+H^_\ MP26C:HHHKVR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J'4[$'!NX? M^^Q5NO.9/]8WU->9F..GA%'E5[W&E<[O^U+#_G[A_P"^Q1_:EA_S]P_]]BN" MHKS/[=J_RHKE.]_M2P_Y^X?^^Q1_:EA_S]P_]]BN"HH_MVK_ "H.4[^/4+.: M01QW,3NW10W)JS7#Z)_R&;;_ 'C_ "-=Q7KY?BY8JFYR5K.Q+5@HHHKO$%%% M% !1110 4444 %%%% !1110!R'B;_D*C_KD/YFL:MGQ-_P A4?\ 7(?S-8U? M$8__ 'J?J:+8****XP"BBB@#T.W_ ./:+_<'\JEJ*W_X]HO]P?RJ6OT&'PHS M"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZS>?V?HMY=@X M:*%F7_>QQ^N*O5RGQ#NO(\+-$#S<3)'^ ^;_ -EH,ZLN6FY'D5%%%2?/!111 M0 445K>&=-_M;Q#9VK#,9??)_NKR?SQC\:!QBY-174]1\%Z.-)\/0[UQ<7'[ MZ7/49Z#\!C\,^.O^1RO_\ MG_Z+6DSAS#^$O7_ #.=HHHI M'D!1110 5[-7C->S4SMP?VOD=%14?VB'_GM'_P!]"C[1#_SVC_[Z%,]>Z)** MC^T0_P#/:/\ [Z%'VB'_ )[1_P#?0H"Z)**C^T0_\]H_^^A2K-$S;5D0D]@P MH"Z'T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBCH,F@ HJO+?6<"[I;N"-?5Y *Q;_ ,;Z%8*<78N''1+< M;\_CT_6@B52$?B9T5>=>./%Z21R:/ITFX'Y;B93Q_N#^I_#UK'U[QWJ&K(UO M;#[':MP0K9=Q[GT]A^M=B<8I+DI_>%%%%(\X**** "K-A92ZC?P6< S M),X4>WO]!UJM7J'@#PTUC!_:MVF+B9<0H1RB'O\ 4_R^M,VH475GRG96=K'9 M64%K",1PH$7Z 8J:BBF>^E;0**** "BBB@ KA/B?_P @VP_Z[-_*N[KA/B?_ M ,@VP_Z[-_*AG/B_X,CS*BBBI/""BBB@ KUWX>?\BI'_ -=G_G7D5>N_#S_D M5(_^NS_SIH[3X4D3/^NE2/]=W_LM> M0UZ9\3YL:=80_P!^9G_(8_\ 9J\SI,\7'.]:W8****1R!1110!U'@"Q^V>*8 MI&&5MD:4_7H/U(/X5[!7GWPOM<0ZA=D?>9(E_#)/\Q7H--'M8*/+23[A1113 M.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@#-U^Q&I:!?6N,L\1*#_:'*_J!7A-?1%>#:U:_8M/TI,\S,(?#(H4444CS0HHHH N:37/22)J***9Z04444 %%%% ')>*/^0G'_UQ'\VK M$K;\4?\ (3C_ .N(_FU8E?$YC_O4_4T6P4445Q %%%% 'H-E_P >-O\ ]N2=&C=D=2K* M<$$_L M??WKH:\WK?T?73%MMKQB8^BR'^'V/M7T.79KM2KOT?\ G_F2T=310"",@Y!H MKZ(D**** "BBB@ HHHH **** "BBB@ HHHH *\YD_P!8WU->C5YS)_K&^IKY M_/MJ?S_0J(VBBBOG"@HHHH T-$_Y#-M_O'^1KN*X?1/^0S;?[Q_D:[BOJAV_P#Q[1?[@_E4 MM16__'M%_N#^52U^@P^%&844450!1110 4444 %%%% !1110 444C.J#+L%' MJ3B@!:*C^T0_\]H_^^A1]HA_Y[1_]]"@5T245']HA_Y[1_\ ?0H^T0_\]H_^ M^A0%T245']HA_P">T?\ WT*/M$/_ #VC_P"^A0%T245']HA_Y[1_]]"C[1#_ M ,]H_P#OH4!=$E%1_:(?^>T?_?0H^T0_\]H_^^A0%T245']HA_Y[1_\ ?0H^ MT0_\]H_^^A0%T245']HA_P">T?\ WT*/M$/_ #VC_P"^A0%T245']HA_Y[1_ M]]"C[1#_ ,]H_P#OH4!=$E%1_:(?^>T?_?0H^T0_\]H_^^A0%T245']HA_Y[ M1_\ ?0H^T0_\]H_^^A0%T245']HA_P">T?\ WT*/M$/_ #VC_P"^A0%T245' M]HA_Y[1_]]"C[1#_ ,]H_P#OH4!=$E%1_:(?^>T?_?0H^T0_\]H_^^A0%T24 M5']HA_Y[1_\ ?0H^T0_\]H_^^A0%T245']HA_P">T?\ WT*/M$/_ #VC_P"^ MA0%T245']HA_Y[1_]]"C[1#_ ,]H_P#OH4!=$E%1_:(?^>T?_?0H^T0_\]H_ M^^A0%T245']HA_Y[1_\ ?0H^T0_\]H_^^A0%T245']HA_P">T?\ WT*/M$/_ M #VC_P"^A0%T245']HA_Y[1_]]"C[1#_ ,]H_P#OH4!=$E%1_:(?^>T?_?0H M^T0_\]H_^^A0%T245']HA_Y[1_\ ?0H^T0_\]H_^^A0%T244=1D44#"BBB@ MHHHH *\\^*%Q\NFVP/4O(P_(#^M>AUY7\2Y=WB"WB[); _B6;_ZU#.7&NU%G M%T445)X@4444 %>@?#&QW3WU^P^XJPH?KR?Y#\Z\_KU_X?6OV?PI%)CF>1Y# M^>W_ -EIHZ\%'FJKR.IHHHIGM!1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !12,RH,LP4>I.*9]HA_Y[1_]]"@+DE%1_:(?^>T?_?0 MH^T0_P#/:/\ [Z% KHDHJ/[1#_SVC_[Z%'VB'_GM'_WT* NB2BH_M$/_ #VC M_P"^A1]HA_Y[1_\ ?0H"Z)**C^T0_P#/:/\ [Z%'VB'_ )[1_P#?0H"Z)**C M^T0_\]H_^^A1]HA_Y[1_]]"@+HDHJ/[1#_SVC_[Z%'VB'_GM'_WT* NB2BH_ MM$/_ #VC_P"^A1]HA_Y[1_\ ?0H"Z)**C^T0_P#/:/\ [Z%'VB'_ )[1_P#? M0H"Z)**C^T0_\]H_^^A1]HA_Y[1_]]"@+HDHJ/[1#_SVC_[Z%'VB'_GM'_WT M* NB2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H"Z)**C^T0_P#/:/\ [Z%'VB'_ M )[1_P#?0H"Z)**C^T0_\]H_^^A1]HA_Y[1_]]"@+HDHJ/[1#_SVC_[Z%'VB M'_GM'_WT* NB2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H"Z)**C^T0_P#/:/\ M[Z%'VB'_ )[1_P#?0H"Z)**C^T0_\]H_^^A1]HA_Y[1_]]"@+HDHJ/[1#_SV MC_[Z%'VB'_GM'_WT* NB2O&?'7_(Y7__ &S_ /1:U[,"",@Y!KQGQU_R.5__ M -L__1:TF<68?PEZ_P"9SM%%%(\@**** "O9J\9KV:F=N#^U\CQVX_X^9?\ M?/\ .HZDN/\ CYE_WS_.HZ1Q/<**** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BK>GZ9>ZI<""RMWFD[[1PON3T ^M>F>&_ =MI;)=:B4N;LTSO_)?_ &6NKK!\&1^5 MX0T]<8RC-^;$_P!:WJH^@H*U**\@HHHH-0HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'/'L'D^+KI MATE5''_?('\Q7L=>5?$N/;XAMW'\=JN?J&;_ .M29Q8Y7I?,XRBBBD>.%%%% M !7NWAZ3S?#FF.$U[=X18/X3TX@Y_=8_(D4T=^7OWVO(VJ*** M9ZP4444 %%%% ')>*/\ D)Q_]<1_-JQ*V_%'_(3C_P"N(_FU8E?$YC_O4_4T M6P4445Q %%%% 'H-E_QXV_\ UR7^53U!9?\ 'C;_ /7)?Y5/7Z!3^!>AF%%% M%6 4444 %%%% !69JND1Z@F]<)< ?*WK[&M.BLZM&%:#A-73 \[G@DMIFBE0 MJZGD&HZ[O4M,AU&':_RR#[D@'(_^M7%W=I-93F&9<,.A[$>HKY#'9?/"ROO' MO_F6G<@HHHKSQA1110 4444 ;.CZV]D1!.2UN>A[I_\ 6KK4=)45T8,K#((/ M!KSFM/2M7ETY]C9>W)^9?3W%>WEV:.E:E6^'OV_X FCM:*C@GCN85EA<,C#@ MBI*^G335T0%%%%, HHHH **** "BBB@ HHHH *\YD_UC?4UZ-7G,G^L;ZFOG M\^VI_/\ 0J(VBBBOG"@HHHH T-$_Y#-M_O'^1KN*X?1/^0S;?[Q_D:[BOJAV_\ Q[1?[@_E4M16_P#Q M[1?[@_E4M?H,/A1F%%%%4 4444 %%%% !1110 4444 %PUXMXV8OXPU G^\ M@_)%%)G#CW^Z7J8%%%%(\@**** "O=?#L/V?PWIL?I;(3]2 3_.O"J^@[5/* MM(8^?D15YZ\"FCTY_,5Y?6OIOB?6-*(%M>R>6/^64AWI^1Z?A3.FC4H MQ?OQ_KT/:K2RM;" 06D$<,8_A1<"IZXG1/B+9WC+#J<8M)3P) XQU%%%!H%%%% !1110 4444 %<)\3_^0;8? M]=F_E7=UPGQ/_P"0;8?]=F_E0SGQ?\&1YE1114GA!1110 5Z[\//^14C_P"N MS_SKR*O7?AY_R*D?_79_YTT=N _B_(ZNBBBF>P%%%% !1110!Y5\3/\ D9+? M_KT7_P!#>N,KL_B9_P C);_]>B_^AO7&4CP<3_&D%%%%(P"BBB@#W'PJNSPM MIHSG]PI_/FM>L?PHQ;PKII/_ #Q _*MBJ/HJ7P+T"BBB@L**** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M KS'XG*!JMBWHHHI MGKA1110 4444 @V7_'C;_\ 7)?Y5/4%E_QXV_\ UR7^53U^@4_@7H9A1115 M@%%%% !1110 4444 %5KVQAOX#%,O^ZPZJ:LT5,X1G%QDKI@<%?Z?-I\_ERC M*G[KCHU5*]"N;6&[@:&9 RG\Q[BN-U/2I=.EY^>%C\K_ -#[U\IF&6RP[YX: MQ_(M.YGT445Y(PHHHH **** +NFZG-ITVY/FC;[\9/!_^O7:6EW#>P":!LJ> MH[@^AKSZK-E?36$XEA;_ 'E/1A7JY?F4L.^2>L?R]!-7._HJI8:A#J$'F1'# M#[R'JM6Z^LA.-2*E%W3("BBBJ **** "BBB@ HHHH *\YD_UC?4UZ-7G,G^L M;ZFOG\^VI_/]"HC:***^<*"BBB@#0T3_ )#-M_O'^1KN*X?1/^0S;?[Q_D:[ MBOJAV__ ![1?[@_E4M1 M6_\ Q[1?[@_E4M?H,/A1F%%%%4 4444 %%%% !1110 4444 %)>+U*^+-1 M!_YZY_,"DS@S#^&O4Q****1Y(4444 %?1%?.]?1%-'I9=]KY?J%%%%,],*** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3XA_\ (J2? M]=D_G7D5>N_$/_D5)/\ KLG\Z\BI,\;'_P 7Y!1112.,**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ KV:O&:]FIG;@_M?(\=N/^/F7_ 'S_ M #J.I+C_ (^9?]\_SJ.D<3W"BBB@ HHJ[I.F3:QJ<-A;M&LLN[:9"0O )YP# MZ4#2;=D4J*[/_A6>L_\ /S8?]_'_ /B*/^%9ZS_S\V'_ '\?_P")IFWU:M_* M<9177_\ "N-<_OVG_?T_X4?\*XUS^_:?]_3_ (4"^KU?Y6 MK_*SD**Z_P#X5QKG]^T_[^G_ H_X5QKG]^T_P"_I_PH#ZO5_E9R%%=?_P * MXUS^_:?]_3_A1_PKC7/[]I_W]/\ A0'U>K_*SD**Z_\ X5QKG]^T_P"_I_PH M_P"%<:Y_?M/^_I_PH#ZO5_E9R%%=?_PKC7/[]I_W]/\ A1_PKC7/[]I_W]/^ M% ?5ZO\ *SD**Z__ (5QKG]^T_[^G_"C_A7&N?W[3_OZ?\* ^KU?Y6K_*SD**Z_P#X5QKG]^T_[^G_ H_X5QKG]^T_P"_I_PH#ZO5_E9R M%%=;)\.M=1^\-:SIREKG3IE0=74;U'XKD4B94:D=7%F5 M11109A1110 5O^'O%E]H$H16,UF3\T#'CZJ>QK HH*A.4'>+/>M)U>SUJR6Z MLY-R'AE/WD/H1V-7J\)T36[K0M06ZMFRIXDC)^61?0_XU[5I>I6VKZ?%>VK9 MCD'0]5/<'W%4>SAL2JJL]RY1110=04444 %%%% !7"?$_P#Y!MA_UV;^5=W7 M"?$__D&V'_79OY4,Y\7_ 9'F5%%%2>$%%%% !7KOP\_Y%2/_KL_\Z\BKUWX M>?\ (J1_]=G_ )TT=N _B_(ZNBBBF>P%%%% !1110!Y?\3@?[:LVQP;?&?\ M@1KAZ[_XH1XN]-DY^9'7\B/\:X"DSPL6K5I!1112.<**** /:?!,GF^$-/.< MX5EZ^CL*WZY'X>8IW7'UP?ZUUU4?04'>E%^04444&H4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !7E7Q+DW>(K=!_!:K^99O_K5ZK7CGCV?SO%UTNV^$%"^$]. _P">6?S)->)5[KX=0Q^&M,4]?LL9Z>J@ MTT=^7KWV_(TZ***9ZP4444 %%%% ')>*/^0G'_UQ'\VK$K;\4?\ (3C_ .N( M_FU8E?$YC_O4_4T6P4445Q %%%% 'H-E_P >-O\ ])HI4#HPP0:?12:35 MF!QFK:-)8,98\O;D]>Z^Q_QK*KT=E5U*L RD8((X-%EWB]U_D)JYZ+165I M.LQWZB.3"7 '([-[C_"M6OKZ-:%:"G!W1 4445J 4444 %%%% !7G,G^L;ZF MO1J\YD_UC?4U\_GVU/Y_H5$;1117SA04444 :&B?\AFV_P!X_P C7<5P^B?\ MAFV_WC_(UW%?4Y'_ )>OZ(F04445[1(4444 %%%% !1110 4444 %%%% '( M>)O^0J/^N0_F:QJV?$W_ "%1_P!I^IHM@HHHKC **** /0 M[?\ X]HO]P?RJ6HK?_CVB_W!_*I:_08?"C,****H HHHH **** "BBB@ HHH MH *Y#XC_ /(L+_U\I_)JZ^L+Q;HMSKVCK9VKQ)()5?,I(& #Z ^M!E7BY4Y) M'BE%=G_PK/6?^?FP_P"_C_\ Q%'_ K/6?\ GYL/^_C_ /Q%(\;ZM6_E.,HK ML_\ A6>L_P#/S8?]_'_^(H_X5GK/_/S8?]_'_P#B* ^K5OY3C**[/_A6>L_\ M_-A_W\?_ .(H_P"%9ZS_ ,_-A_W\?_XB@/JU;^4XRBNS_P"%9ZS_ ,_-A_W\ M?_XBC_A6>L_\_-A_W\?_ .(H#ZM6_E.,HKL_^%9ZS_S\V'_?Q_\ XBC_ (5G MK/\ S\V'_?Q__B* ^K5OY3C**[/_ (5GK/\ S\V'_?Q__B*/^%9ZS_S\V'_? MQ_\ XB@/JU;^4XRBNS_X5GK/_/S8?]_'_P#B*/\ A6>L_P#/S8?]_'_^(H#Z MM6_E.,HKL_\ A6>L_P#/S8?]_'_^(H_X5GK/_/S8?]_'_P#B* ^K5OY3C**[ M/_A6>L_\_-A_W\?_ .(H_P"%9ZS_ ,_-A_W\?_XB@/JU;^4XRBNS_P"%9ZS_ M ,_-A_W\?_XBC_A6>L_\_-A_W\?_ .(H#ZM6_E.,HKL_^%9ZS_S\V'_?Q_\ MXBC_ (5GK/\ S\V'_?Q__B* ^K5OY3C**[/_ (5GK/\ S\V'_?Q__B*/^%9Z MS_S\V'_?Q_\ XB@/JU;^4XRBNS_X5GK/_/S8?]_'_P#B*/\ A6>L_P#/S8?] M_'_^(H#ZM6_E.,HKL_\ A6>L_P#/S8?]_'_^(H_X5GK/_/S8?]_'_P#B* ^K M5OY3C**[/_A6>L_\_-A_W\?_ .(H_P"%9ZS_ ,_-A_W\?_XB@/JU;^4XRBNS M_P"%9ZS_ ,_-A_W\?_XBC_A6>L_\_-A_W\?_ .(H#ZM6_E.,HKL_^%9ZS_S\ MV'_?Q_\ XBC_ (5GK/\ S\V'_?Q__B* ^K5OY3C**[/_ (5GK/\ S\V'_?Q_ M_B*/^%9ZS_S\V'_?Q_\ XB@/JU;^4XRBNS_X5GK/_/S8?]_'_P#B*/\ A6>L M_P#/S8?]_'_^(H#ZM6_E.,HKL_\ A6>L_P#/S8?]_'_^(H_X5GK/_/S8?]_' M_P#B* ^K5OY3C**[/_A6>L_\_-A_W\?_ .(H_P"%9ZS_ ,_-A_W\?_XB@/JU M;^4XRBNS_P"%9ZS_ ,_-A_W\?_XBC_A6>L_\_-A_W\?_ .(H#ZM6_E/3-/\ M^0;:_P#7%/Y"K-16L30VD,3$%DC53CID"I:9[JV"BBB@84444 %>+>-5*^,- M0!_O*?S137M->.^/H]GB^Z;'WTC;_P = _I29PX]?NEZG,T444CR HHHH *^ M@;*02V%O(.CQ*PQ[@5\_5[GX9G^T>&--DSG_ $=5)]U&#_*FCT,O?O21JT44 M4SU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E/B' M_P BI)_UV3^=>15Z[\0_^14D_P"NR?SKR*DSQL?_ !?D%%%%(XPHHHH **W- M$\*ZCKUM)/9M $C?8?,<@YQGT]ZT_P#A7&N?W[3_ +^G_"@UC0J25TCD**Z_ M_A7&N?W[3_OZ?\*/^%<:Y_?M/^_I_P *8_J]7^5G(45U_P#PKC7/[]I_W]/^ M%'_"N-<_OVG_ ']/^% ?5ZO\K.0HKK_^%<:Y_?M/^_I_PH_X5QKG]^T_[^G_ M H#ZO5_E9R%%=?_ ,*XUS^_:?\ ?T_X4?\ "N-<_OVG_?T_X4!]7J_RLY"B MNO\ ^%<:Y_?M/^_I_P */^%<:Y_?M/\ OZ?\* ^KU?Y6K_ M "LY"BNO_P"%<:Y_?M/^_I_PH_X5QKG]^T_[^G_"@/J]7^5G(45U_P#PKC7/ M[]I_W]/^%'_"N-<_OVG_ ']/^% ?5ZO\K.0HKK_^%<:Y_?M/^_I_PH_X5QKG M]^T_[^G_ H#ZO5_E9R%%=?_ ,*XUS^_:?\ ?T_X4?\ "N-<_OVG_?T_X4!] M7J_RLY"BNO\ ^%<:Y_?M/^_I_P */^%<:Y_?M/\ OZ?\* ^KU?Y6,U[-3.W!_:^1X[!?^1RL/^VG_ *+:N=KHO O_ ".5 MA_VT_P#1;4&E'^+'U1[-1115'T(4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/:YX.TO6D9_*6VNCR) MHE R?]H=_P"?O7E.LZ+>:'>FVO(\9Y1UY5QZ@U[O65XAT.'7M*DM9 !*/FAD MQ]QO\/6D<>(PL:BO'<\,HJ2>"2VN)()D*2QL4=3V(X-1TCQ@HHHH *ZOP+KQ MTK5UM)GQ:79"MGHK_P +?T/_ -:N4HZ'(H+IS<)*2/HBBLKPWJ)U7P]9W;', MC)MD/^TO!_,C/XUJU1]#&2DDUU"BBB@84444 %<)\3_^0;8?]=F_E7=UPGQ/ M_P"0;8?]=F_E0SGQ?\&1YE1114GA!1110 5Z[\//^14C_P"NS_SKR*O7?AY_ MR*D?_79_YTT=N _B_(ZNBBBF>P%%%% !1110!P7Q0BS8Z?-_M_$6#S?"_F8_U,Z/^>5_]FKR2DSQ<RTT>S@9\U*W8**** M9V!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %>#:U=?;=/TKVC7K_^S=!O;O.&CB.P M_P"T>%_4BO"*3/,S"?PQ"BBBD>:%%%% !7T#91?9["WAQCRXE3'T %>#Z=!] MJU2TM\9\V9$_-@*]_IH]/+E\3"BBBF>D%%%% !1110!R7BC_ )"-O_ -(=OD5@ZQH0GW7-HH$O5D'1O<>]?/YCE5[U: M"]5_E_D4FD45SNCZ]NVVUXWS=$E/?V/^ M-=%7V&&Q-/$0YX/_ (!#5@HHHKH$%%%% !7G,G^L;ZFO1J\YD_UC?4U\_GVU M/Y_H5$;1117SA04444 :&B?\AFV_WC_(UW%/\C7<5]3D?\"7 MK^B)D%%%%>T2%%%% !1110 4444 %%%% !1110!R'B;_ )"H_P"N0_F:QJV? M$W_(5'_7(?S-8U?$8_\ WJ?J:+8****XP"BBB@#T.W_X]HO]P?RJ6HK?_CVB M_P!P?RJ6OT&'PHS"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M *\I^)46SQ'#(.DELI_$,P_PKU:O.OBA!\^FW '42(?T(_K0SDQJO19YY111 M4GBA1110 5ZY\.[KS_"ZPYYMYG3'L?F_]F->1UW?PRO_ "]1O+%CQ-&)%SZJ M<']#^E-'5@I\M9>9Z;1113/;"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** .4^(?_(J2?\ 79/YUY%7KOQ#_P"14D_Z[)_.O(J3/&Q_ M\7Y!1112.,**** /4?AE_P @2\_Z^?\ V45V]<1\,O\ D"7G_7S_ .RBNWJC MW<+_ 8A1110= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !7C/CK_DO^9SM%%%(\@**** "O9J\9KV:F=N#^U\CQVX_X^9? M]\_SJ.I+C_CYE_WS_.HZ1Q/<**** "NB\"_\CE8?]M/_ $6U<[71>!?^1RL/ M^VG_ *+:@TH_Q8^J/9J***H^A"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)_B+IPM->2[1<) M=Q[C_OKP?TV_G7'UZC\3++ARUF%%%%(Y@HH MHH ]4^&DQ?0+B(G/EW!(YZ J/ZYKM*X3X8?\@V__ .NR_P J[NJ/=PKO1B%% M%%!T!1110 5PGQ/_ .0;8?\ 79OY5W=<)\3_ /D&V'_79OY4,Y\7_!D>9444 M5)X04444 %>N_#S_ )%2/_KL_P#.O(J]=^'G_(J1_P#79_YTT=N _B_(ZNBB MBF>P%%%% !1110!D>*;;[7X7U&+&<0EP/=?F_I7AU?0SHLD;(XRK @CU%> 7 MELUG?3VK_>AD:,_4'%)GEYA'6,B"BBBD><%%%% #HY'BE26-BKHP92.Q%>]: M5?IJFE6U['C$T88@=CW'X'(KP.O1/AMK(_?:/,WK+!G_ ,>']?SIH[<#5Y9\ MKZGHE%%%,]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBFR2)%&TDC!40%F8] !U- '"?$S4O+L[734;YI M6\V0?[(X'YG/Y5YI6GXAU5M9UNYO>?+9ML0/9!P/\?QK,I'@8BI[2HY!1112 M,0HHHH W_!=M]J\6V*X.V-C(?;:"1^N*]IKS+X8V>_4KV\(XBB$8/NQS_P"R M_K7IM-'LX&-J5^X4444SL"BBB@ HHHH Y+Q1_P A./\ ZXC^;5B5M^*/^0G' M_P!<1_-JQ*^)S'_>I^IHM@HHHKB **** /0;+_CQM_\ KDO\JGJ"R_X\;?\ MZY+_ "J>OT"G\"]#,****L HHHH **** "BBB@ HHHH **** "BBB@ HHHH MR-7T5+X&:'"7 _)_K[^]R(AG)>W/3U3Z>WM771R)+&KQL&1AD$=#7V&#QM/%0O'?JB&K#J***[!!7G, MG^L;ZFO1J\YD_P!8WU-?/Y]M3^?Z%1&T445\X4%%%% &AHG_ "&;;_>/\C7< M5P^B?\AFV_WC_(UW%?4Y'_ EZ_HB9!1117M$A1110 4444 %%%% !1110 44 M44 I^IHM@HHHKC **** M/0[?_CVB_P!P?RJ6HK?_ (]HO]P?RJ6OT&'PHS"BBBJ **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH *X_XCVOG>&DF Y@G5B?8@K_,BNPK+\1V?V_P MY?VP&6:$E1ZL.1^H%!E6CS4VCPNBBBI/GPHHHH *T-#U$Z3K=I>\[8I!OQW4 M\-^A-9]% XMQ=T?0ZL'4,I!4C(([TM(SD]4_A/]/PKJ MZH^AIS4XJ2ZA11106%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110!RGQ#_P"14D_Z[)_.O(J]=^(?_(J2?]=D_G7D5)GC8_\ B_(****1QA11 M10!ZC\,O^0)>?]?/_LHKMZXCX9?\@2\_Z^?_ &45V]4>[A?X,0HHHH.@**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ KQGQU_P CE?\ _;/_ -%K7LU>,^.O^1RO_P#MG_Z+6DSAS#^$ MO7_,YVBBBD>0%%%% !7LU>,U[-3.W!_:^1X[X4444 %=%X%_Y'*P_P"VG_HMJYVNB\"_\CE8?]M/_1;4&E'^+'U1 M[-1115'T(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110!RGQ# /A1^.DR8KR*O6OB-($\+A3_P M M+A%'Y$_TKR6DSQL=_%^04444CC"BBB@#TWX8?\@V_P#^NR_RKNZX3X8?\@V_ M_P"NR_RKNZH]W"?P8A1110= 4444 %<)\3_^0;8?]=F_E7=UPGQ/_P"0;8?] M=F_E0SGQ?\&1YE1114GA!1110 5Z[\//^14C_P"NS_SKR*O7?AY_R*D?_79_ MYTT=N _B_(ZNBBBF>P%%%% !1110 5X_X^L/L?BB60#"7*+*/KT/ZC/XU[!7 M$_$G3?M&D0WZ+EK9\-_N-Q_/'YT,Y<9#FI/RU/+:***D\0**** "I[*\FT^] MAN[=MLL3!E/^>U044 G9W1[SHVJP:SI<-[ 1AQ\RYY1NZFK]>,>$_$LGA_4, M2$M93$"9!V]&'N/U'X5['!/%O%KJZFO;J6YN'+S2L69CW-)G!C<1RQY([LAHHHI'DA1110 445-:6TE[>0V ML0S),X1?J3B@$KZ'K'P^L/LGAA)F&'N9&EY].@_EG\:ZJHK6WCM+2&VB&(XD M"*/8#%2U1]%3AR04>P4444%A1110 4444 -O_UR7^53U!9?\>-O_P!< ME_E4]?H%/X%Z&844458!1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 4M1TV'48=D@VR#[CCJO_UJXR\LYK&HKT"J]Y90WT!BF7([,. MJGVKR\PRV.)7/#27Y^HT['G]%7-0TZ;3IMD@RA^ZX'#?_7JG7R=2G*G)QFK- M%A1114 %%%% !6EI6KRZ=)M.7@8_,GI[BLVBM:56=*:G!V: ]$@GBN85EA<. MC="*DKA-.U.;3IMR?-&?OH3P?_KUVEI>0WL EA;(/4'JI]#7UV!S"&*C9Z2[ M?Y$-6)Z\YD_UC?4UZ-7G,G^L;ZFO/S[:G\_T'$;1117SA04444 :&B?\AFV_ MWC_(UW%/\C7<5]3D?\"7K^B)D%%%%>T2%%%% !1110 4444 M%%%% !1110!R'B;_ )"H_P"N0_F:QJV?$W_(5'_7(?S-8U?$8_\ WJ?J:+8* M***XP"BBB@#T.W_X]HO]P?RJ6HK?_CVB_P!P?RJ6OT&'PHS"BBBJ **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** /!M;L3IFMWEGC BE(7_=ZK M^A%4*[KXEZ;Y6I6VHHORSIY;G_:7I^8/Z5PM2?/UXWP3Q75O'/"X>*10R,.A!KY[KMO WBL:=*-+ MOI,6DC?NG8\1,>Q]C^A_&FCNP>(Y'R2V9ZE1113/7"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH Y3XA_P#(J2?]=D_G7D5>N_$/_D5)/^NR M?SKR*DSQL?\ Q?D%%%%(XPHHHH ]1^&7_($O/^OG_P!E%=O7$?#+_D"7G_7S M_P"RBNWJCW<+_!B%%%%!T!1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %>,^.O\ DO^9SM%%%(\@**** "O9J\9KV:F=N#^U\ MCQVX_P"/F7_?/\ZCJ2X_X^9?]\_SJ.D<3W"BBB@ KHO O_(Y6'_;3_T6U<[7 M1>!?^1RL/^VG_HMJ#2C_ !8^J/9J***H^A"BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1F5$9W8* MJC))/ % 'GOQ/O!ML+$'G+3,/T'_ +-7G5:WB75O[:UVXNU)\K.R('L@Z?GU M_&LFD>!B*GM*CD@HHHI&(4444 >G?#%3_95\W8S@?DO_ ->NZKC?AK%L\.32 M$$%%%% !7KOP\_P"14C_Z[/\ SKR*O7?A MY_R*D?\ UV?^=-';@/XOR.KHHHIGL!1110 4444 %5[ZTCO[">TF'[N9"C>V M1UJQ10)JZLSY^O+26QO9K288DA?U)X%:FZ+YM"D%M<[I=/8\J.6C/JO^%#4U>&:)XAO]!N/,M),QL?GA?E'_#U]Q7J. MA>,M,UH+&7%M='@PRMU/^R>_\_:G<]BABX5-'HSHJ***9UA1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !113)IHK>)I9I$CC499W; 'XT M/K$\1>)K/P_;9E(EN6'[N!3R?<^@]ZYOQ!\1(HPUOHP\Q^AN77Y1_N@]?J?U MKSNXN)KNX>>XE:65SEG4VV[L****!!1110 5VWPXTDW.K2:C(O[NU7:F1U<_X#/YBN+CC>65(X MU+.[!54=23T%>X^'=(71-%@LQ@R ;I6'\3GK_A] *:.O!4N>IS/9&K1113/: M"BBB@ HHHH **** .2\4?\A./_KB/YM6)6WXH_Y"F21I-&TN#&X"&*CVDMF M-.QYU16OJ^BO8L9HJU%5"Z?J,.HP>9&<,/OH>JFN$D_P!8WU-/MKF6 MTG6:%RKK^M1D[F)/*IP4E[RO?\!)6$HHHKSQA1110!H:)_R&;;_> M/\C7<5P^B?\ (9MO]X_R-=Q7U.1_P)>OZ(F04445[1(4444 %%%% !1110 4 M444 %%%% '(>)O\ D*C_ *Y#^9K&K9\3?\A4?]I^IHM@HH MHKC **** /0[?_CVB_W!_*I:BM_^/:+_ '!_*I:_08?"C,****H HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH QO%6D_VSX?N+9%S,H\R'_>' M;\1D?C7B%?1%>/>.-$.DZXTT:8MKLF1,= W\0_/G\:3/-Q]*Z51',4444CS MHHHH **** .[\'^-OL:QZ;JLA, ^6*<\^7[-[>_;Z=/3%97171@RL,A@<@BO MGBNB\/>,+_02(L_:+//,+G[O^Z>W\J=SOPV,Y?=J;'LU%9.C>(],UR,&TG'F MXRT+\./P[_49K6IGJQDI*Z"BBB@84444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110!RGQ#_P"14D_Z[)_.O(J]=^(?_(J2?]=D_G7D5)GC8_\ B_(****1QA11 M10!ZC\,O^0)>?]?/_LHKMZXCX9?\@2\_Z^?_ &45V]4>[A?X,0HHHH.@**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ KQGQU_P CE?\ _;/_ -%K7LU>,^.O^1RO_P#MG_Z+6DSAS#^$ MO7_,YVBBBD>0%%%% !7LU>,U[-3.W!_:^1X[X4444 %=%X%_Y'*P_P"VG_HMJYVM_P %316_BZQEFD2.-?,R[L ! M^[;N:#2C_$CZH]IHJE_;&F?]!&T_[_K_ (T?VQIG_01L_P#O^O\ C5'O\T>Y M=HK._M_1O^@O8?\ @2G^-']OZ-_T%[#_ ,"4_P : YX]S1HK._M_1O\ H+V' M_@2G^-']OZ-_T%[#_P "4_QH#GCW-&BL[^W]&_Z"]A_X$I_C1_;^C?\ 07L/ M_ E/\: YX]S1HK._M_1O^@O8?^!*?XT?V_HW_07L/_ E/\: YX]S1HK._M_1 MO^@O8?\ @2G^-']OZ-_T%[#_ ,"4_P : YX]S1HK._M_1O\ H+V'_@2G^-'] MOZ-_T%[#_P "4_QH#GCW-&BL[^W]&_Z"]A_X$I_C1_;^C?\ 07L/_ E/\: Y MX]S1HK._M_1O^@O8?^!*?XT?V_HW_07L/_ E/\: YX]S1HK._M_1O^@O8?\ M@2G^-']OZ-_T%[#_ ,"4_P : YX]S1HK._M_1O\ H+V'_@2G^-']OZ-_T%[# M_P "4_QH#GCW-&BL[^W]&_Z"]A_X$I_C1_;^C?\ 07L/_ E/\: YX]S1HK._ MM_1O^@O8?^!*?XT?V_HW_07L/_ E/\: YX]S1HK._M_1O^@O8?\ @2G^-']O MZ-_T%[#_ ,"4_P : YX]S1HK)E\4:%""6U6U./[D@;^6:Q;[XC:/;*1:K-=O MVVKL7\SS^E!$JU..\D=@2 ,DX KS7QMXQ2ZC?2M,DW1$XGG4\/\ [*^WJ>_T MZX6M^,=4UM6A9Q;VK=88N 1_M'J?Y>U<]2N>=B,9SKEAL%%%%(X HHHH *** ML6%H]_J%O:1_?FD5 ?3)ZT E=V1['X-M3:>$[!",,Z&4^^XDC]"*W:9%$D$, M<48PB*%4>@' I]4?1PCRQ4>P4444%!1110 5PGQ/_P"0;8?]=F_E7=UPGQ/_ M .0;8?\ 79OY4,Y\7_!D>94445)X04444 %>N_#S_D5(_P#KL_\ .O(J]=^' MG_(J1_\ 79_YTT=N _B_(ZNBBBF>P%%%% !1110 4444 5[ZSAU"QFL[A=T4 MRE6']?K7ANL:7/HVIS65P/F0_*V.'7L17O5_XTFTC=;H\;HISH\4C1R*5=2596&"".QIM(\4**** "BBB@ HHHH MZ/2/&NL:2%C\X7, _P"6<_.!['J/Y5VVF_$32+L*MV)+.0]=PW)^8_J!7DU% M,Z*>*JT]$[H^@K:\MKV/S+6XBG3^]&X8?I4U?/44TMO()(97C<=&1B"/Q%;M MGXUU^SP!?-,H_AF4/G\3S^M%SLAF$?M(]HHKS.V^)]XN/M6G02^IB?9749_P!C:P_F*=SHCBZ+ZG;T5S$7C_P])]ZYEB_WX6_H#5M/&/A^ M0<:G$/\ >##^8H-%6IO:2-RBLH>)=#8@#5K/GUE J3^W]&_Z"]A_X$I_C05[ M2'P_\"4_QH'SQ[FC16:WB'15&3J]C MQZ7"'^M1-XIT)!SJMK^#Y_E0+VD.YKT5S\GC;P[%UU)2?]F-V_D*I3?$70H_ MN&YE_P!R+'\R*"77I+>2.MHK@+CXH6XS]FTR5_0R2!?Y UD77Q)U>;(MX;:W M'8A2S#\SC]*+F4L9176YZM6;J&OZ5I>?ME]#&PZH&W-_WR.:\=O?$>LZAD7. MHSLIZJK;5/X+@5ETKG//,/Y%]YZ/JGQ,0!DTNS+'_GK/P/P4?XUP^IZUJ.L2 M[[ZZ>7!RJ9PJ_0#BJ%%!Q5*]2I\3"BBBD8A1110 4444 %%%;/AKP_-X@U(0 M+E+=,-/*!]U?3ZGM0.,7)\J.D^'GAXSW']LW*?NHB5MP?XF[M^'\_I7I=16U MO%:6T=O @2*-0J*.P%2U1[]"DJ4.5!1110:A1110 4444 %%%% ')>*/^0G' M_P!<1_-JQ*V_%'_(3C_ZXC^;5B5\3F/^]3]31;!1117$ 4444 >@V7_'C;_] MAF%%%%6 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 (RAE*L 5(P01UKE=8T(V^ZXM06AZLG M=?I[5U=%/\C7<5]3D?\"7K^B)D%%%%>T2%%%% !1110 4444 %%%% !1110!R'B;_ M )"H_P"N0_F:QJV?$W_(5'_7(?S-8U?$8_\ WJ?J:+8****XP"BBB@#T.W_X M]HO]P?RJ6HK?_CVB_P!P?RJ6OT&'PHS"BBBJ **** "BBB@ HHHH **** "B MBH;F[MK.+S;JXB@CSC?*X49],F@&[$U%9W]OZ-_T%[#_ ,"4_P :/[?T;_H+ MV'_@2G^-!//'N:-%9W]OZ-_T%[#_ ,"4_P :/[?T;_H+V'_@2G^- <\>YHT5 MG?V_HW_07L/_ )3_&C^W]&_Z"]A_P"!*?XT!SQ[FC16=_;^C?\ 07L/_ E/ M\:/[?T;_ *"]A_X$I_C0'/'N:-%9W]OZ-_T%[#_P)3_&C^W]&_Z"]A_X$I_C M0'/'N:-%9W]OZ-_T%[#_ ,"4_P :/[?T;_H+V'_@2G^- <\>YHT5G?V_HW_0 M7L/_ )3_&C^W]&_Z"]A_P"!*?XT!SQ[FC16=_;^C?\ 07L/_ E/\:/[?T;_ M *"]A_X$I_C0'/'N:-%9W]OZ-_T%[#_P)3_&C^W]&_Z"]A_X$I_C0'/'N:-% M9W]OZ-_T%[#_ ,"4_P :/[?T;_H+V'_@2G^- <\>YHT5G?V_HW_07L/_ )3 M_&C^W]&_Z"]A_P"!*?XT!SQ[FC16=_;^C?\ 07L/_ E/\:/[?T;_ *"]A_X$ MI_C0'/'N:-%9W]OZ-_T%[#_P)3_&C^W]&_Z"]A_X$I_C0'/'N:-%9W]OZ-_T M%[#_ ,"4_P :/[?T;_H+V'_@2G^- <\>YHT5G?V_HW_07L/_ )3_&C^W]&_ MZ"]A_P"!*?XT!SQ[FC16=_;^C?\ 07L/_ E/\:/[?T;_ *"]A_X$I_C0'/'N M:-%9W]OZ-_T%[#_P)3_&C^W]&_Z"]A_X$I_C0'/'N:-%9W]OZ-_T%[#_ ,"4 M_P :/[?T;_H+V'_@2G^- <\>YHT5G?V_HW_07L/_ )3_&C^W]&_Z"]A_P"! M*?XT!SQ[FC16=_;^C?\ 07L/_ E/\:/[?T;_ *"]A_X$I_C0'/'N:-%9W]OZ M-_T%[#_P)3_&C^W]&_Z"]A_X$I_C0'/'N:-%9W]OZ-_T%[#_ ,"4_P :/[?T M;_H+V'_@2G^- <\>YHT4BLKJ&4AE(R"#P12T%!1110 4444 %%%% !63XCT6 M/7M'EM&P)1\\+G^%QT_ ]/QK6HH)E%27*SY[FADMIY()D*2QL5=3U!'45'7I MOCWPN;N-M7LH\SQK^_11RZC^+ZC^7TKS*I/!K472GRL****#(**** "BBB@! MR.T;JZ,593D,IP0:ZO2?B#JM@%CN]M["./WAPX_X%W_$&N2HH+A4G!WB['L6 MF^.]#OPJR3FTD/\ #.,#_OKI^=='%+'/&)(I$D0]&1@0?QKYZJ>VO;JRDWVM MS- WK&Y7^5.YVPS"2^-7/H&BO'+3QYK]K@- M,^CPO_0&F;+$4G]I'2T5BIXNT"3&W5(!D_Q97^8J9?$FB.<#5K+\9E'\S06J MD'U1J45G?V_HW_07L/\ P)3_ !H_M_1O^@O8?^!*?XT#YX]S1HK._M_1O^@O M8?\ @2G^-']OZ-_T%[#_ ,"4_P : YX]S1HK._M_1O\ H+V'_@2G^-']OZ-_ MT%[#_P "4_QH#GCW-&BL[^W]&_Z"]A_X$I_C1_;^C?\ 07L/_ E/\: YX]S1 MHK._M_1O^@O8?^!*?XT?V_HW_07L/_ E/\: YX]S1HK._M_1O^@O8?\ @2G^ M-']OZ-_T%[#_ ,"4_P : YX]S1HK._M_1O\ H+V'_@2G^-']OZ-_T%[#_P " M4_QH#GCW-&BL[^W]&_Z"]A_X$I_C1_;^C?\ 07L/_ E/\: YX]S1HK._M_1O M^@O8?^!*?XT?V_HW_07L/_ E/\: YX]S1HK._M_1O^@O8?\ @2G^-']OZ-_T M%[#_ ,"4_P : YX]S1HK._M_1O\ H+V'_@2G^-']OZ-_T%[#_P "4_QH#GCW M-&BL[^W]&_Z"]A_X$I_C5BUU&ROBPM+RWN"GWA%*KX^N#0"G%[,LT444%!11 M10 4444 14F>-C_ .+\@HHH MI'&%%%% 'J/PR_Y EY_U\_\ LHKMZXCX9?\ ($O/^OG_ -E%=O5'NX7^#$** M**#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH *\9\=?\CE?_\ ;/\ ]%K7LU>,^.O^1RO_ /MG_P"B MUI,XS4SMP?VOD>.W'_'S+_OG^=1U)@]S["O*O! M<.L[KRRVPWV.<\++]?0^_P"=*QY^*PG-[\-SR2BIKNTN+&Y>VNH7BF0X9&&" M*AI'E-6T84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 445N^'O"U[X@F!0&*T4_/.PX^@]305" M$IOEBBIHFB7>NWZVMJN .9)"/EC7U/\ A7L^CZ1:Z)IZ6=JORCEG/5V[DTNE M:39Z-9+:V<6U!RS'[SGU)[FKU4>SAL,J2N]PHHHH.H**** "BBB@ HHHH ** M** .2\4?\A./_KB/YM6)6WXH_P"0G'_UQ'\VK$KXG,?]ZGZFBV"BBBN( HHH MH ]!LO\ CQM_^N2_RJ>H++_CQM_^N2_RJ>OT"G\"]#,****L HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+6-#%SNN+4 M3=63L_\ ]>MVBL,1AZ>(AR5$"9YPRLC%6!# X((Z4E=EJ^BI?J98L)< =>S? M7_&N0EB>&1HY%*NIP0>U?(8S!5,+.TM5T9HG<91117$ 4444 %%%% !1110! MH:)_R&;;_>/\C7<5P^B?\AFV_P!X_P C7<5]3D?\"7K^B)D%%%%>T2%%%% ! M1110 4444 %%%% !1110!R'B;_D*C_KD/YFL:MGQ-_R%1_UR'\S6-7Q&/_WJ M?J:+8****XP"BBB@#T.W_P"/:+_<'\JEJ*W_ ./:+_<'\JEK]!A\*,PHHHJ@ M"BBB@ HHHH **** "BBB@ KD/B/_ ,BPO_7RG\FKKZY#XC_\BPO_ %\I_)J# M'$_PI>AY-1114G@!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% 'O^G_ /(-M?\ KBG\A5FJVG_\@VU_ZXI_(59JCZ2.R"BBB@84444 M%%%% !1110 5YEXU\'&U>35--BS;GF:%!_JS_> _N_R^G3TVB@RK48U8\K/G M>BO1_%7@/S"]]HR ,?FDMAW]T_P_+TKSIT:-V1U*LIPRL,$&I/$JT94I6D-H MHHH,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "O0/A=_Q\ZE_N1_S:O/Z] ^%W M_'SJ7^Y'_-J9T83^-$](HHHIGNA1110 4444 H_#+_D"7G_7S_[**[>N(^&7 M_($O/^OG_P!E%=O5'NX7^#$****#H"BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\9\=?\ (Y7_ /VS M_P#1:U[-7C/CK_DS4 MSMP?VOD>.W'_ !\R_P"^?YU'4EQ_Q\R_[Y_G4=(XGN%%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !4D$,MS.D,,;22N=JHHR2:N:3HM_K=SY-E 7Q M]YSPB?4UZOX;\)V?A^+S.)[UAAYB.GLH[#]33.BAAI57Y$?A'PLF@6AEGVO? MS#YV'.P?W1_4_P"%=+113/:A",(\L0HHHH+"BBB@ HHHH *X3XG_ /(-L/\ MKLW\J[NN$^)__(-L/^NS?RH9SXO^#(\RHHHJ3P@HHHH *]=^'G_(J1_]=G_G M7D5>N_#S_D5(_P#KL_\ .FCMP'\7Y'5T444SV HHHH **** "BBB@ HHHH * M*** ,S6= T_7;?R[R++*/DE7AT^A_H>*\OU[P5J6C%I8U-U:#_EK&.5'^TO; MZ]*]CHH.>MAH5=7HSYWHKV76/!6D:N6D$7V:X;GS8>,GW7H?Y^]<'JO@'6-/ M+/ @O81_%#][\5Z_EFE8\NKA*D.ETD_#21BLF MK701>ODPG2HPI*T4%%% M%!J%%%% !1110 4444 %%%% !1110!R7BC_D)Q_]<1_-JQ*V_%'_ "$X_P#K MB/YM6)7Q.8_[U/U-%L%%%%<0!1110!Z#9?\ 'C;_ /7)?Y5/4%E_QXV__7)? MY5/7Z!3^!>AF%%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 5GZII,6HQYX291\KX_0^U:%%9U:4*L'":NF!YY M<6TMI.T,R%7';UJ*N]U#3H=1@V2###[CCJIKB[VRFL)S%,O^ZPZ,/:ODL?E\ M\,^9:Q[_ .9:=RM1117FC"BBB@ HHHH T-$_Y#-M_O'^1KN*X?1/^0S;?[Q_ MD:[BOJAV_\ Q[1?[@_E M4M16_P#Q[1?[@_E4M?H,/A1F%%%%4 4444 %%%% !1110 4444 %$M/UY3(Z^ M1=XXG0'?^=;]%!,X1FK21X?K7AG4]"D/VF'=!GY9X^4/^!^M8]?0[*KJ M590RD8((R#7):Q\/M,U M+9DV4QYP@RA_P" ]OPI6/-JX!K6F>2T5T&J>#-: MTLEFM3<0C_EI;_./Q'4?E7/]#@TC@E"4':2L%%%%!(4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 5Z!\+O^/G4O]R/^;5Y_7H'PN_X^=2_W(_YM3.C"?QHGI%%%%,]T**** "B MBB@#E/B'_P BI)_UV3^=>15Z[\0_^14D_P"NR?SKR*DSQL?_ !?D%%%%(XPH MHHH ]1^&7_($O/\ KY_]E%=O7$?#+_D"7G_7S_[**[>J/=PO\&(4444'0%%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 5XSXZ_Y'*_\ ^V?_ *+6O9J\9\=?\CE?_P#;/_T6M)G#F'\) M>O\ F<[1112/("BBB@ KV:O&:]FIG;@_M?(\=N/^/F7_ 'S_ #J.NVE\![Y7 M;^TL98G_ %'_ -E3/^$"_P"HG_Y _P#LJ1B\-5['&45V?_"!?]1/_P @?_94 M?\(%_P!1/_R!_P#94!]6J]CC**[/_A O^HG_ .0/_LJ/^$"_ZB?_ ) _^RH# MZM5['&45V?\ P@7_ %$__('_ -E1_P (%_U$_P#R!_\ 94!]6J]CC**[/_A MO^HG_P"0/_LJ/^$"_P"HG_Y _P#LJ ^K5>QQE%=G_P (%_U$_P#R!_\ 94?\ M(%_U$_\ R!_]E0'U:KV.,HKL_P#A O\ J)_^0/\ [*C_ (0+_J)_^0/_ +*@ M/JU7L<9179_\(%_U$_\ R!_]E1_P@7_43_\ ('_V5 ?5JO8XRBNS_P"$"_ZB M?_D#_P"RH_X0+_J)_P#D#_[*@/JU7L<9179_\(%_U$__ "!_]E1_P@7_ %$_ M_('_ -E0'U:KV.,HKL_^$"_ZB?\ Y _^RH_X0+_J)_\ D#_[*@/JU7L<9179 M_P#"!?\ 43_\@?\ V5'_ @7_43_ /('_P!E0'U:KV.,HKL_^$"_ZB?_ ) _ M^RH_X0+_ *B?_D#_ .RH#ZM5['&45V?_ @7_43_ /('_P!E1_P@7_43_P#( M'_V5 ?5JO8XRBNS_ .$"_P"HG_Y _P#LJ/\ A O^HG_Y _\ LJ ^K5>QQE%= MG_P@7_43_P#('_V5'_"!?]1/_P @?_94!]6J]CC**[/_ (0+_J)_^0/_ +*C M_A O^HG_ .0/_LJ ^K5>QQE%=HO@#L6_PWT2(YE>ZG]FD 'Z ']:V[/PWHU@0;?38%8=&9=[# M\6R:+&T[L>/Z;X>U75B/LEE*Z'_EHPVI^9XKM](^&L,9675KCSF'_+&$ MD+^+=3^&*[ZBBQUT\%3AK+4AM;6WLK=8+6%(8EZ(BX%3444SL2L%%%% !111 M0 4444 %%%% !7"?$_\ Y!MA_P!=F_E7=US7C'1/[;M+:/[1Y/ER%L[-V>/J M*##$Q?\BI'_P!=G_G7*_\ M"!?]1/\ \@?_ &5=UX5TS^R-$6U\[S<2,V[;MZ^V331U8.C.%2\ET-NBBBF> MH%%%% !1110 4444 %%%% !1110 4444 %%%% %2^TNPU)-E[:0SCL74$CZ' MJ*Y>^^&VE7&6LYY[5CT&?,4?@>?UKLZ*#.=&G/XD>47GPWUB#)MI;>Y7L VQ MOR/'ZUAW7AK6K+/GZ9<@#JRIO _%I[%E(_P#0:+&;P-5=CRNBO2G^%]L<;-3E M'KF('^M5IOACY432?VOG:,X^S?\ V=%B'@ZRZ?D>?45V?_"!?]1/_P @?_94 M?\(%_P!1/_R!_P#94B?JU7L<9179_P#"!?\ 43_\@?\ V5'_ @7_43_ /(' M_P!E0'U:KV.,HKL_^$"_ZB?_ ) _^RJ2'X>^=,L?]J8W=_L__P!E0'U:KV.( MHKT9?A<@^_J['TQ;X_\ 9JL)\,+$?ZS4+EN/X54?XT[%K!5NQYC17K,?PWT- M/O/>2?[T@_HHJ]#X'\.P\C3PY]7D<_IG%%BU@*KWL>,5/;V5U=G%M;33'TCC M+?RKW*WT/2;7!@TVT0C^(0KG\\9J\ , = *+&LOD\;@J\\1.48Z-]T6GH8E%;?\ PCW_ $]? M^0__ *]'_"/?]/7_ )#_ /KUR_V?B?Y?Q7^8[F)16W_PCW_3U_Y#_P#KT?\ M"/?]/7_D/_Z]']GXG^7\5_F%SIK+_CQM_P#KDO\ *IZCMT\NVBCSG:@&?7 J M2OLZ:M!)F844458!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 57O+.&^@,4RY!Z'NI]15BBIE&,XN,E=,#A- M1TV;3IMKC=&?N.!P?_KU2KT2>"*YA:*9 Z-U!KF9?#@65E6Z.T'C*?\ UZ^8 MQN4SISO1UB_P+3,&BMO_ (1[_IZ_\A__ %Z/^$>_Z>O_ "'_ /7KB_L_$_R_ MBO\ ,=S$HK;_ .$>_P"GK_R'_P#7H_X1[_IZ_P#(?_UZ/[/Q/\OXK_,+E31/ M^0S;?[Q_D:[BN-F,\?6NCKZ'**,Z-%QFK._Z(F04445Z MI(4444 %%%% !1110 4444 %%%% '(>)O^0J/^N0_F:QJZO6-*^VWHE\[9\@ M&-F?7WK/_P"$>_Z>O_(?_P!>ODL9@J\\1.48Z-]T6GH8E%;?_"/?]/7_ )#_ M /KT?\(]_P!/7_D/_P"O7-_9^)_E_%?YCN8E%;?_ CW_3U_Y#_^O1_PCW_3 MU_Y#_P#KT?V?B?Y?Q7^87.HM_P#CVB_W!_*I:9$NR%%SG"@9I]?:1TBC,*** M*H HHHH **** "BBB@ HHHH *Y#XC_\ (L+_ -?*?R:NOK"\6Z5_;&CK;>=Y M.)5?=LW= >V1ZT&5>+E3DD>*45V?_"!?]1/_ ,@?_94?\(%_U$__ "!_]E4G MC?5JO8XRBNS_ .$"_P"HG_Y _P#LJ/\ A O^HG_Y _\ LJ ^K5>QQE%=G_P@ M7_43_P#('_V5'_"!?]1/_P @?_94!]6J]CC**[/_ (0+_J)_^0/_ +*C_A O M^HG_ .0/_LJ ^K5>QQE%=G_P@7_43_\ ('_V5'_"!?\ 43_\@?\ V5 ?5JO8 MXRBNS_X0+_J)_P#D#_[*C_A O^HG_P"0/_LJ ^K5>QQE%=G_ ,(%_P!1/_R! M_P#94?\ "!?]1/\ \@?_ &5 ?5JO8XRBNS_X0+_J)_\ D#_[*C_A O\ J)_^ M0/\ [*@/JU7L<9179_\ "!?]1/\ \@?_ &5'_"!?]1/_ ,@?_94!]6J]CC** M[/\ X0+_ *B?_D#_ .RH_P"$"_ZB?_D#_P"RH#ZM5['&45V?_"!?]1/_ ,@? M_94?\(%_U$__ "!_]E0'U:KV.,HKL_\ A O^HG_Y _\ LJ/^$"_ZB?\ Y _^ MRH#ZM5['&45V?_"!?]1/_P @?_94?\(%_P!1/_R!_P#94!]6J]CC**[/_A O M^HG_ .0/_LJ/^$"_ZB?_ ) _^RH#ZM5['&45V?\ P@7_ %$__('_ -E1_P ( M%_U$_P#R!_\ 94!]6J]CC**[/_A O^HG_P"0/_LJ/^$"_P"HG_Y _P#LJ ^K M5>QQE%=G_P (%_U$_P#R!_\ 94?\(%_U$_\ R!_]E0'U:KV.,HKL_P#A O\ MJ)_^0/\ [*C_ (0+_J)_^0/_ +*@/JU7L<9179_\(%_U$_\ R!_]E1_P@7_4 M3_\ ('_V5 ?5JO8XRBNS_P"$"_ZB?_D#_P"RH_X0+_J)_P#D#_[*@/JU7L<9 M179_\(%_U$__ "!_]E1_P@7_ %$__('_ -E0'U:KV.,HKL_^$"_ZB?\ Y _^ MRH_X0+_J)_\ D#_[*@/JU7L>F:?_ ,@VU_ZXI_(59J*UC\JTACSG9&JYQUP* MEJCW5L%%%% PHHHH **** "BBB@ HHHH **** "BBB@ K-U#0-*U3)O+&&1C M_'C:W_?0YK2HH$XJ2LT<+??#.QE):QO9H#_=D4./Z'^=<[>?#O7+?)A6"Z7M MYXL;.[ M_P"/FT@F_P"ND8;^=*QSRR]?9D?/]%>VS>$- N/OZ7"/^N>4_P#02*H2_#S0 M)#\L<\7^Y*?ZYHL9/ 5%LT>0T5ZC)\,M+/\ J[V\7C^(J?Z"J[_"^ Y\O59% M]-T(/]118S>"K=CS:BN^N?AK]FC#_P!K;LG&/LV/_9JJ?\(%_P!1/_R!_P#9 M4$/"U5NOR.,HKL_^$"_ZB?\ Y _^RH_X0+_J)_\ D#_[*D'U:KV.,HKL_P#A M O\ J)_^0/\ [*C_ (0+_J)_^0/_ +*@/JU7L<9179_\(%_U$_\ R!_]E1_P M@7_43_\ ('_V5 ?5JO8XRBNS_P"$"_ZB?_D#_P"RH_X0+_J)_P#D#_[*@/JU M7L<9179_\(%_U$__ "!_]E1_P@7_ %$__('_ -E0'U:KV.,HKL_^$"_ZB?\ MY _^RH_X0+_J)_\ D#_[*@/JU7L<9179_P#"!?\ 43_\@?\ V5'_ @7_43_ M /('_P!E0'U:KV.,HKL_^$"_ZB?_ ) _^RH_X0+_ *B?_D#_ .RH#ZM5['&4 M5V?_ @7_43_ /('_P!E1_P@7_43_P#('_V5 ?5JO8XRBNS_ .$"_P"HG_Y M_P#LJ/\ A O^HG_Y _\ LJ ^K5>QQE%=G_P@7_43_P#('_V5'_"!?]1/_P @ M?_94!]6J]CC*] ^%W_'SJ7^Y'_-JI?\ "!?]1/\ \@?_ &5=1X-\/?V)-=M] MJ\[S54?ZO;C&?<^M,WPU"I&JFT=;1113/7"BBB@ HHHH Y3XA_\ (J2?]=D_ MG7D5>V^*M,_M?1&M?.\K,BMNV[NGMD5PO_"!?]1/_P @?_94F>7C*,YU+Q1Q ME%=G_P (%_U$_P#R!_\ 94?\(%_U$_\ R!_]E2.7ZM5['&45V?\ P@7_ %$_ M_('_ -E1_P (%_U$_P#R!_\ 94!]6J]C>^&7_($O/^OG_P!E%=O7.>#]&_L7 M3IX/M'G;Y=^=FW' 'J?2NCJCV,/%QI),****#8**** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQGQU_R M.5__ -L__1:U[-7G_B3PC_:FOW5Y]N\KS-GR>5NQA0.NX>E)G)C82G32CW/- MZ*[/_A O^HG_ .0/_LJ/^$"_ZB?_ ) _^RI'F?5JO8XRBNS_ .$"_P"HG_Y M_P#LJ/\ A O^HG_Y _\ LJ ^K5>QQE>S5QG_ @7_43_ /('_P!E7H'V#_IK -_P".TSKPM&<;W1__V0$! end GRAPHIC 7 guzjsxkjfy3c000002.jpg GRAPHIC begin 644 guzjsxkjfy3c000002.jpg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end